Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of LP-005 injection in complement-mediated kidney diseases
CTR20260135Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in Complement 3 glomerulopathy (C3G), membranoproliferative glomerulonephritis (MPGN), lupus nephritis (LN), thrombotic microangiopathies (TMA), anti-glomerular basement membrane disease, sponsored by LongBio Pharma. Started Jan 2026; status: active.
02
Drugs
LP-005
03
Conditions
Complement 3 glomerulopathy (C3G)membranoproliferative glomerulonephritis (MPGN)lupus nephritis (LN)thrombotic microangiopathies (TMA)anti-glomerular basement membrane disease
Beyond the preview
Go deeper on CTR20260135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260135.